F S&P 500
5,538.75 +1.75 (+0.03%) F Dow Jones
39,507.00 -19.00 (-0.05%) F Nasdaq
19,986.25 +14.00 (+0.07%) E-mini Russell 2000 Index Futur
2,043.40 -1.50 (-0.07%) Petróleo
81.23 +0.40 (+0.49%) Oro
2,328.40 -2.40 (-0.10%)
Oneness Biotech Co., Ltd. (4743.TWO)
Oneness Biotech Co., Ltd.
No.236, Xinyi Road
11th Floor Sec. 4 Da’an district
Taipei 106
Taiwan
886 2 2703 1098
https://www.onenessbio.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Nien-Yi Chen | Deputy General Manager of Antibody New Drug Division; | 6.03M | N/D | N/D |
| Ms. Shuling Cheng Ph.D. | President | N/D | N/D | N/D |
| Ms. Wen-Tzu Hsiao | Acting Spokesperson & Senior Manager of Finance Department | N/D | N/D | N/D |
| Wen Ci Xiao | Accounting Supervisor | N/D | N/D | N/D |
| Dr. Jui-Ching Chen Ph.D. | Director of New Drug Development Department | N/D | N/D | N/D |
| Mr. Kung-Ming Lu | Director of Operation Center | N/D | N/D | N/D |
| Mr. Tzu-Chun Yang | Associate General Manager of Information Technology Department | 2.14M | N/D | N/D |
Descripción
Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation segments. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-cancer drug that is in Phase I clinical trials. It is also developing FB825, which is in Phase IIa clinical trial for treating atopic dermatitis and allergic asthma; FB704A that has completed Phase I clinical trial for the treatment of rheumatoid arthritis; OB318, an anticancer botanical drug of antrodia cinnamomea; SNS812, for the treatment of COVID-19 that is in Phase I clinical trials; and FB918 for the treatment of asthma. In addition, the company engages in the management of agriculture cultivation and trading business; and production and sale of agricultural products. Oneness Biotech Co., Ltd. was incorporated in 2008 and is headquartered in Taipei, Taiwan.
Gestión corporativa
La calificación ISS Governance QuickScore de Oneness Biotech Co., Ltd. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
